Oddity Tech Ltd

ODD

Oddity Tech Ltd. operates as a consumer tech company that builds digital-first brands for the beauty and wellness industries in the United States, Israel, and internationally. It serves consumers through its platform, which uses data science, machine learning, and computer vision capabilities to identify consumer needs, and develop solutions in the form of beauty, wellness, and technology products.

About the company

Country: IsraelPrice: $17.63Market Cap: $813.2M

Investment snapshot

47%positive consensus

Scored 1d ago

Positive

BUY / PASS

Neutral / negative

3 / 6

NEUTRAL / FAIL

Median fair value

$18.73

+6.3% vs price

Models with upside

2 / 17

Positive margin of safety

Strongest signal

5 of 8 pass — Lynch, Sleep and Neff object

Key risk

Split decision: 7 PASS · 6 FAIL · 3 NEUTRAL

Framework analysis

Verdict	Meaning
BUY	Positive purchase signal: the framework's buy requirements are met.
PASS	The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRAL	Neither a positive nor negative conclusion. It does not mean to hold an existing position.
FAIL	The company does not clear the framework's requirements.
Ranked	Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

Metric	Graham Defensive Value	Buffett Quality Compounder	Lynch GARP	Greenblatt Magic Formula	Piotroski F-Score	Dreman Contrarian Value	Munger Quality Focus	Pabrai Dhandho Framework	Akre Three-Legged Stool	Marks Risk-Aware Value	Ackman Activist Value	Templeton Global Bargain Hunter	Sleep Scale Economies Shared	Asness Systematic Factors	Neff Low-P/E Total Return	Schloss Asset-Value Discipline	O'Shaughnessy Systematic Factor Composite
Verdict	PASS	PASS	FAIL	BUY · Rank #79 (Top 2.6%)	PASS	PASS	PASS	NEUTRAL	FAIL	NEUTRAL	PASS	PASS	FAIL	FAIL	FAIL	FAIL	NEUTRAL
Score
Analysis	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…	Checking access…
Intrinsic Value (annual)	N/A	N/A		N/A	N/A		N/A	N/A	N/A		N/A		N/A	N/A	N/A	N/A	N/A
Margin of Safety	N/A	N/A	+60.8%	N/A	N/A	+20.6%	N/A	N/A	N/A	-15.5%	N/A	-15.5%	N/A	N/A	N/A	N/A	N/A
Financial Basis	Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 · Market data at 2026-11-01 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 · Market data at 2026-11-01 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14	Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-03-17 Score computed: 2026-11-14

Where It Passes

Growth63% pass✓ 9✗ 4▾
5 of 8 pass — Lynch, Sleep and Neff object
EPS Growth (3-yr avg, 10-yr window)355.4%
✓Graham>= 33% growth
Basic earnings-growth PEG (dividends excluded)0.16
✓Lynch< 1.0 (ideally < 0.5)
3-5 Year EPS CAGR62.2%
✓Lynch15-30% (Fast Grower); > 0% to pass
Inventory Growth vs Revenue GrowthInv: 35.4% vs Rev: 25.2%
✗LynchInventory growth < Revenue growth
EPS Growth Direction$0.26 (2021) -> $1.80 (2025)
✓DremanPositive over recent years
EPS CAGR62.2% CAGR over 4 years
✓Dreman> 5% annualized
Positive Net Income Frequency5/5 years positive
✓MarksPositive net income in >= 7 of last 10 years
3yr Median Revenue Growth27.2%
✓Ackman>= 5%
Positive EPS Growth Frequency4/4 years with positive EPS growth
✓AckmanPositive EPS growth in >= 3 of last 5 years
5-Year EPS CAGR62.2% CAGR over 4 years
✓Templeton> 0% (5-year EPS CAGR)
Revenue growth vs. gross and operating margin trendgross margin 70.4% -> 72.7%, operating margin 14.6% -> 14.7%
✗SleepRevenue rising; gross margin flat or falling; operating margin holding
5-year Revenue CAGR
✗SleepCAGR > 7%
3-5 Year Diluted EPS CAGR62.2% over 4 years
✗Neff7%-20% annualized
Verdicts57% pass✓ 8✗ 6▾
Split decision: 7 PASS · 6 FAIL · 3 NEUTRAL
Overall verdict
✓GrahamPASS (4/9)✓BuffettPASS (5/9)✗LynchFAIL (3/7)✓GreenblattRank #79✓PiotroskiPASS (F-Score 5)✓DremanPASS (6/11)✓MungerPASS (2/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (2/6)•MarksNEUTRAL (4/5)✓AckmanPASS (4/9)✓TempletonPASS (4/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1062/2370 (Top 44.8%))✗NeffFAIL (3/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
Profitability56% pass✓ 25✗ 10▾
9 of 16 pass — Graham, Buffett, Piotroski +4 more object
Positive EPS (10 years)5/6 years positive
✗GrahamPositive EPS every year for 10 years
EPS Growth (3-yr avg, 10-yr window)355.4%
✓Graham>= 33% growth
Net Income Positive (10+ years)5/6 years positive
✗BuffettPositive every year for 10+ years
ROE (up to 5-year arithmetic mean)25.4%
✓Buffett> 15% arithmetic mean (app rule)
Operating Margin (10-yr trend)14.7% (latest)
✓BuffettStable or rising over 10 years
Free Cash Flow Proxy$117.5M
✓BuffettPositive and growing
Earnings Variance (10-yr CoV)0.62
✗BuffettCoV < 0.3
Retained Earnings Effectiveness
✗Buffett$1 retained -> > $1 market value created
Basic earnings-growth PEG (dividends excluded)0.16
✓Lynch< 1.0 (ideally < 0.5)
3-5 Year EPS CAGR62.2%
✓Lynch15-30% (Fast Grower); > 0% to pass
ROE27.9%
✓Lynch> 15%
EBIT / Enterprise Value11.9%
✓Greenblatt> 10%
Earnings Yield + ROC AssessmentEY=11.9%, ROC=124.2%
✓GreenblattBoth EY > 10% and ROC > 25%
Net Income / Total Assets9.73%
✓PiotroskiROA > 0
ROA Change YoY23.12% -> 9.73% (delta: -13.39%)
✗PiotroskiCurrent ROA > Prior ROA
(CFO / Total Assets) vs ROACFO/Assets=7.70%, ROA=9.73%
✗PiotroskiCFO/Assets > ROA
Gross Margin Change YoY72.4% -> 72.7%
✓PiotroskiImproved YoY
Pre-Tax Income / Revenue16.8%
✓Dreman>= 8%
Net Income / Shareholders' Equity27.9%
✓Dreman> 12%
Margin of SafetyP/E=9.8x
✓PabraiP/B < 1.5 or P/E < 15
Return on Equity28.2% (3-yr avg)
✓AkreROE > 20% (3-year avg)
Discount to Intrinsic Value20.6% (IV=$22.20 vs Price=$17.63)
✓Marks>= 20% below intrinsic value
Positive Net Income Frequency5/5 years positive
✓MarksPositive net income in >= 7 of last 10 years
Operating Income / Revenue14.7%
✗Ackman>= 15%
Net Income / Shareholders Equity27.9%
✓Ackman>= 15%
5-Year EPS CAGR62.2% CAGR over 4 years
✓Templeton> 0% (5-year EPS CAGR)
Operating Margin Trend14.6% (2023) -> 14.7% (2025)
✓TempletonNon-negative operating-margin trend over 3 years
Revenue growth vs. gross and operating margin trendgross margin 70.4% -> 72.7%, operating margin 14.6% -> 14.7%
✗SleepRevenue rising; gross margin flat or falling; operating margin holding
Net income / market capitalization+13.62%; #423/6340 (top 6.7%)
✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
Gross profit / total assets+51.74%; #632/3702 (top 17.1%)
✓AsnessTop 30% of eligible cross-section
Net income / positive book equity+27.93%; #502/5226 (top 9.6%)
✓AsnessTop 30% of eligible cross-section
Negative 5-year standard deviation of ROA-0.0541; #2673/5884 (top 45.4%)
✗AsnessTop 30% of eligible cross-section
3-5 Year Diluted EPS CAGR62.2% over 4 years
✗Neff7%-20% annualized
Positive Diluted-EPS Years5/5 years positive
✓Schloss>= 70% positive over 5-10 observed years (app rule)

Where It Falls Short

Debt & Leverage8% pass✓ 3✗ 12▾
11 of 12 flag ODD's debt & leverage — Graham, Buffett, Lynch +8 more
LT Debt vs Net Current Assets
✗GrahamLT Debt <= Net Current Assets
Debt/Equity & Interest CoverageD/E: 1.47, IC: N/A
✗BuffettD/E < 0.5 AND Interest Coverage > 5x
Total Debt / Equity1.47
✗Lynch< 0.33
Cash - Long-term Debt
✗LynchPositive preferred
LT Debt / Total Assets Change0.00% -> 0.00%
✓PiotroskiDecreased YoY
Current Assets / Current Liabilities5.24
✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
Total Debt / Shareholders' Equity1.47
✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
Debt Levels1.47
✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
Interest Coverage & Debt/EBITDAIC=N/A (no interest expense), D/EBITDA=4.5x
✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
Total Debt / Shareholders Equity1.47
✗Ackman<= 1.0
Negative debt-to-equity (higher means less debt)-1.4738; #3575/4210 (top 84.9%)
✗AsnessTop 30% of eligible cross-section
Valuation38% pass✓ 13✗ 15▾
8 of 13 flag ODD's valuation — Graham, Dreman, Ackman +5 more
Price / 3-yr avg EPS11.9x
✓Graham<= 15x
Price-to-Book Ratio
✗Graham<= 1.5x
P/E x P/B
✗Graham<= 22.5
Basic earnings-growth PEG (dividends excluded)0.16
✓Lynch< 1.0 (ideally < 0.5)
EBIT / Enterprise Value11.9%
✓Greenblatt> 10%
Earnings Yield + ROC AssessmentEY=11.9%, ROC=124.2%
✓GreenblattBoth EY > 10% and ROC > 25%
Price / EPS9.8x
✓Dreman< 12x✓Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
Price / (CFO / Shares)
✗Dreman< 8x
Price / Book Value per Share
✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
Valuation ReasonablenessP/E=9.8x
✓MungerP/E < 25 or Owner Earnings Yield > 5%
P/E or FCF YieldP/E=9.8x, FCF Yield=10.3%
✓PabraiP/E < 15 or FCF Yield > 10%
P/B or P/E vs. Historical AverageP/E=9.8x
✓MarksP/E < 15 or P/B < 2.0
Discount to Intrinsic Value20.6% (IV=$22.20 vs Price=$17.63)
✓Marks>= 20% below intrinsic value
Price / FCF per Share
✗Ackman<= 25
Price vs. Trailing Low150% of trailing low ($11.77)
✗Templeton<= 120% of trailing low (certified split-adjusted live window)
Net income / market capitalization+13.62%; #423/6340 (top 6.7%)
✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
Positive book equity / market capitalization+0.4876; #2931/6449 (top 45.4%)
✗AsnessTop 30% of eligible cross-section
Price / Diluted EPS9.8x
✓NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
(EPS CAGR % + Dividend Yield %) / P/E
✗Neff> 0.7 (Neff's published traditional edge)
Price / Tangible Book Value per Share
✗SchlossP/TBV <= 1.00x (app cutoff)
Book Value per Share Change
✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
Revenue / market capitalization+0.9959; #1780/5247 (top 33.9%)
✗OshaughnessyTop 10% of eligible cross-section
(Operating cash flow - capex) / market capitalization+10.29%; #729/4519 (top 16.1%)
✗OshaughnessyTop 10% of eligible cross-section
Trailing six-month price return through the evaluation date+23.11%; #1223/6202 (top 19.7%)
✗OshaughnessyTop 10% of eligible cross-section
Cash Flow50% pass✓ 6✗ 6▾
5 of 10 pass — Lynch, Piotroski, Dreman +2 more object
Free Cash Flow Proxy$117.5M
✓BuffettPositive and growing
FCF Positive and Growing$83.6M
✗LynchPositive and growing
Operating Cash Flow$87.6M
✓PiotroskiCFO > 0
(CFO / Total Assets) vs ROACFO/Assets=7.70%, ROA=9.73%
✗PiotroskiCFO/Assets > ROA
Price / (CFO / Shares)
✗Dreman< 8x
P/E or FCF YieldP/E=9.8x, FCF Yield=10.3%
✓PabraiP/E < 15 or FCF Yield > 10%
FCF Positive5/5 years FCF positive
✓MarksPositive FCF in majority of recent years
(OCF - CapEx) / Market Cap
✗Ackman>= 4%
Price / FCF per Share
✗Ackman<= 25
Positive Operating Cash Flow frequency5/5 years positive
✓SleepPositive OCF in >= 70% of available years
Operating Cash Flow - Capital Expenditures$83.6M
✓Neff> $0 (app proxy for a strong fundamental case)
(Operating cash flow - capex) / market capitalization+10.29%; #729/4519 (top 16.1%)
✗OshaughnessyTop 10% of eligible cross-section
Efficiency50% pass✓ 6✗ 5▾
4 of 8 pass — Piotroski, Munger, Akre +1 more object
Current Ratio5.24
✓Graham>= 2.0
ROIC (3-5 yr avg)25.8%
✓Buffett> 10%
ROIC - WACC+15.8%
✓BuffettPositive (WACC = 10%)
EBIT / (NWC + Net Fixed Assets)124.2%
✓Greenblatt> 25%
Current Ratio Change YoY1.79 -> 5.24
✓PiotroskiIncreased YoY
Revenue / Total Assets Change YoY1.47x -> 0.71x
✗PiotroskiImproved YoY
Current Assets / Current Liabilities5.24
✓Dreman> 1.5
Return on Invested Capital9.6%
✗Munger> 15%
ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=9.6%
✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
Reinvestment Rate x ROIC9.6% (RR=100% x ROIC=9.6%)
✗AkreReinvestment Rate * ROIC > 10%
ROIC (5-year)1/2 years above 12% (latest 9.6%)
✗SleepROIC > 12% in a majority of years
Valuation models50% pass✓ 2✗ 2▾
Models split on ODD at $17.63 — fair values range $15.27–$45.00
Lynch fair value$45.00
✓Lynch+60.8% margin vs $17.63
Dreman fair value$22.20
✓Dreman+20.6% margin vs $17.63
Marks fair value$15.27
✗Marks-15.5% margin vs $17.63
Templeton fair value$15.27
✗Templeton-15.5% margin vs $17.63

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Consumer Goods

SIC Sector: Chemicals & Pharmaceuticals

Size: Small Cap($813.2M)

Revenue: $809.8M+25.2% YoY

Net Income: $110.7M+9.1% YoY

Financial Snapshot

Operating Margin14.7%

Return on Equity27.9%

Debt / Equity1.47

Current Ratio5.24

EPS (Diluted)$1.80+9.8% 1y

Similar Companies

CLCOLGATE PALMOLIVE CO

$79.2B

ELESTEE LAUDER COMPANIES INC

$40.5B

Shareholder Return

Fiscal 2025

Share retirement not available for this company.

Buybacks: —
Dividends: —

What drove EPS

A buyback raises earnings per share without the company earning more. This splits each year's change into the two.

FY22

50.0% = 56.1% + −3.9%

FY23

156.4% = 169.4% + −4.8%

FY24

64.0% = 73.4% + −5.4%

FY25

9.8% = 9.1% + 0.6%

Earnings Fewer shares More shares

The two parts do not sum exactly to the total — the difference is the cross-term, plus preferred capital where the company has any. It is left visible rather than distributed into the other two.

Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

Metric	FY 2025 Sources 20-F · 2026-03-17	FY 2024 Sources 20-F · 2025-02-25	FY 2023 Sources 20-F · 2024-03-06	FY 2022 Sources 20-F · 2024-03-06	FY 2021 Sources 20-F · 2024-03-06
Market Cap	$813.2Mcurrent	--	--	--	--
Revenue	$809.8M↑25%	$647.0M↑27%	$508.7M↑57%	$324.5M↑46%	$222.6M
Operating Income	$118.8M↑3%	$115.6M↑56%	$74.3M↑169%	$27.7M↑42%	$19.5M
Net Income	$110.7M↑9%	$101.5M↑73%	$58.5M↑169%	$21.7M↑56%	$13.9M
EPS (Diluted)	$1.80↑10%	$1.64↑64%	$1.00↑156%	$0.39↑50%	$0.26
Gross Margin	72.7%	72.4%↑3%	70.4%↑5%	67.2%↓2%	68.8%
Operating Margin	14.7%↓18%	17.9%↑22%	14.6%↑71%	8.5%↓3%	8.8%
ROE	27.9%↓22%	36.0%↑74%	20.7%↓6%	22.0%↑9%	20.3%
Total Debt	$584.4M	--	--	$3.9M	--
Shareholders' Equity	$396.5M↑40%	$282.3M	$283.1M↑187%	$98.7M↑44%	$68.6M
Current Ratio	5.24↑193%	1.79↓13%	2.05↑27%	1.61	—
Debt / Equity	1.47	—	—	0.04	—
Operating Cash Flow	$87.6M↓36%	$137.8M↑58%	$87.5M↑124%	$39.0M↑282%	$10.2M
Free Cash Flow	$83.6M↓38%	$134.5M↑58%	$85.4M↑133%	$36.7M↑367%	$7.9M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Consumer Goods

ODD vs Peers — Financial Grading

Revenue$809.8MBottom 25%

Net Income$110.7MBottom 25%

ROE27.9%Median

D/E1.47Median

Op. Margin14.7%Median

Curr. Ratio5.24Top 25%

Company	Market Cap	Price	Revenue	Net Income	ROE	D/E	Op. Margin	Curr. Ratio	Graham	Buffett	Lynch	Greenblatt	Piotroski	Dreman
UNILEVER PLCUL	$142.6B	$66.21	$59.3B	$11.1B	61.0%	1.68	17.9%	0.79	2/9	4/9	4/7	1/3	F-Score 8	6/11
ECOLAB INC.ECL	$86.7B	$309.27	$16.1B	$2.1B	21.2%	0.84	17.0%	1.08	3/9	5/9	3/7	1/3	F-Score 6	5/11
COLGATE PALMOLIVE COCL	$79.2B	$99.67	$20.4B	$2.1B	3948.1%	147.89	16.2%	0.83	2/9	5/9	3/7	1/3	F-Score 5	3/11
ESTEE LAUDER COMPANIES INCEL	$40.5B	$111.75	$14.3B	$1.1B	-29.3%	1.89	-5.5%	1.30	2/9	4/9	2/7	0/3	F-Score 6	1/11
CHURCH & DWIGHT CO INC /DE/CHD	$26.7B	$113.00	$6.2B	$736.8M	18.4%	0.55	17.4%	1.07	3/9	7/9	3/7	1/3	F-Score 7	4/11
CANON INCCAJPY	$25.2B	$30.28	—	—	—	—	—	—	3/9	1/9	1/7	1/3	F-Score 7	5/11
SOMNIGROUP INTERNATIONAL INC.SGI	$14.0B	$60.76	$7.5B	$384.1M	12.4%	1.51	10.1%	0.83	1/9	5/9	2/7	1/3	F-Score 5	2/11
INTERPARFUMS INCIPAR	$4.3B	$133.37	$1.5B	$168.4M	19.1%	0.20	18.2%	2.99	4/9	5/9	6/7	1/3	F-Score 5	7/11